Mental impairment in cytogenetically positive fragile X females

A. Cronister, Randi J Hagerman, M. Wittenberger, K. Amiri

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Prenatal diagnosis is now available to fragile X (fra[X]) syndrome families and has proven reliable when testing male fetuses. It has been reported that approximately one-third of heterozygous fra(X) females demonstrate mental impairment. Based on this, families usually continue pregnancies involving a female fetus. The purpose of this study is to investigate whether a 35% risk for mental impairment is appropriate when counseling heterozygous women carrying fra(X)-positive female fetuses. Forty-three cytogenetically positive (≥2%) daughters of known fra(X) carrier women were ascertained postnatally in an unbiased fashion. Their mother's carrier status was determined on the basis of at least one son with Martin-Bell syndrome. In addition to peripheral blood cytogenetic studies, all daughters had cognitive testing to determine full-scale IQ. In this study, 55.8% (24/43) were mentally impaired (IQ <85) compared with the expected 35%. Of these, 42% were mentally retarded (IQ <70). Although we do not know the correlation between percent fragility by peripheral blood compared with the percent fragility by amniocentesis or CVS, we assume that they are relatively comparable such that a female who is positive with ≥2% fragility would probably be positive by all methods. This report suggests that the penetrance of mental impairment in females with a percent fragility of ≥2% may be as high as 55%. Further studies are necessary to clarify this issue so that accurate information can be given in genetic counseling.

Original languageEnglish (US)
Pages (from-to)503-504
Number of pages2
JournalAmerican Journal of Medical Genetics
Volume38
Issue number2-3
DOIs
StatePublished - 1991
Externally publishedYes

Fingerprint

Nuclear Family
Fragile X Syndrome
Fetus
Amniocentesis
Penetrance
Mentally Disabled Persons
Genetic Counseling
Prenatal Diagnosis
Cytogenetics
Counseling
Mothers
Pregnancy

Keywords

  • family counseling
  • heterozygous fragile X female
  • Martin Bell syndrome

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Mental impairment in cytogenetically positive fragile X females. / Cronister, A.; Hagerman, Randi J; Wittenberger, M.; Amiri, K.

In: American Journal of Medical Genetics, Vol. 38, No. 2-3, 1991, p. 503-504.

Research output: Contribution to journalArticle

Cronister, A. ; Hagerman, Randi J ; Wittenberger, M. ; Amiri, K. / Mental impairment in cytogenetically positive fragile X females. In: American Journal of Medical Genetics. 1991 ; Vol. 38, No. 2-3. pp. 503-504.
@article{d07c6a07fbe34df7a4fb33d79b61ce12,
title = "Mental impairment in cytogenetically positive fragile X females",
abstract = "Prenatal diagnosis is now available to fragile X (fra[X]) syndrome families and has proven reliable when testing male fetuses. It has been reported that approximately one-third of heterozygous fra(X) females demonstrate mental impairment. Based on this, families usually continue pregnancies involving a female fetus. The purpose of this study is to investigate whether a 35{\%} risk for mental impairment is appropriate when counseling heterozygous women carrying fra(X)-positive female fetuses. Forty-three cytogenetically positive (≥2{\%}) daughters of known fra(X) carrier women were ascertained postnatally in an unbiased fashion. Their mother's carrier status was determined on the basis of at least one son with Martin-Bell syndrome. In addition to peripheral blood cytogenetic studies, all daughters had cognitive testing to determine full-scale IQ. In this study, 55.8{\%} (24/43) were mentally impaired (IQ <85) compared with the expected 35{\%}. Of these, 42{\%} were mentally retarded (IQ <70). Although we do not know the correlation between percent fragility by peripheral blood compared with the percent fragility by amniocentesis or CVS, we assume that they are relatively comparable such that a female who is positive with ≥2{\%} fragility would probably be positive by all methods. This report suggests that the penetrance of mental impairment in females with a percent fragility of ≥2{\%} may be as high as 55{\%}. Further studies are necessary to clarify this issue so that accurate information can be given in genetic counseling.",
keywords = "family counseling, heterozygous fragile X female, Martin Bell syndrome",
author = "A. Cronister and Hagerman, {Randi J} and M. Wittenberger and K. Amiri",
year = "1991",
doi = "10.1002/ajmg.1320380272",
language = "English (US)",
volume = "38",
pages = "503--504",
journal = "American Journal of Medical Genetics",
issn = "1552-4825",
publisher = "Wiley-Liss Inc.",
number = "2-3",

}

TY - JOUR

T1 - Mental impairment in cytogenetically positive fragile X females

AU - Cronister, A.

AU - Hagerman, Randi J

AU - Wittenberger, M.

AU - Amiri, K.

PY - 1991

Y1 - 1991

N2 - Prenatal diagnosis is now available to fragile X (fra[X]) syndrome families and has proven reliable when testing male fetuses. It has been reported that approximately one-third of heterozygous fra(X) females demonstrate mental impairment. Based on this, families usually continue pregnancies involving a female fetus. The purpose of this study is to investigate whether a 35% risk for mental impairment is appropriate when counseling heterozygous women carrying fra(X)-positive female fetuses. Forty-three cytogenetically positive (≥2%) daughters of known fra(X) carrier women were ascertained postnatally in an unbiased fashion. Their mother's carrier status was determined on the basis of at least one son with Martin-Bell syndrome. In addition to peripheral blood cytogenetic studies, all daughters had cognitive testing to determine full-scale IQ. In this study, 55.8% (24/43) were mentally impaired (IQ <85) compared with the expected 35%. Of these, 42% were mentally retarded (IQ <70). Although we do not know the correlation between percent fragility by peripheral blood compared with the percent fragility by amniocentesis or CVS, we assume that they are relatively comparable such that a female who is positive with ≥2% fragility would probably be positive by all methods. This report suggests that the penetrance of mental impairment in females with a percent fragility of ≥2% may be as high as 55%. Further studies are necessary to clarify this issue so that accurate information can be given in genetic counseling.

AB - Prenatal diagnosis is now available to fragile X (fra[X]) syndrome families and has proven reliable when testing male fetuses. It has been reported that approximately one-third of heterozygous fra(X) females demonstrate mental impairment. Based on this, families usually continue pregnancies involving a female fetus. The purpose of this study is to investigate whether a 35% risk for mental impairment is appropriate when counseling heterozygous women carrying fra(X)-positive female fetuses. Forty-three cytogenetically positive (≥2%) daughters of known fra(X) carrier women were ascertained postnatally in an unbiased fashion. Their mother's carrier status was determined on the basis of at least one son with Martin-Bell syndrome. In addition to peripheral blood cytogenetic studies, all daughters had cognitive testing to determine full-scale IQ. In this study, 55.8% (24/43) were mentally impaired (IQ <85) compared with the expected 35%. Of these, 42% were mentally retarded (IQ <70). Although we do not know the correlation between percent fragility by peripheral blood compared with the percent fragility by amniocentesis or CVS, we assume that they are relatively comparable such that a female who is positive with ≥2% fragility would probably be positive by all methods. This report suggests that the penetrance of mental impairment in females with a percent fragility of ≥2% may be as high as 55%. Further studies are necessary to clarify this issue so that accurate information can be given in genetic counseling.

KW - family counseling

KW - heterozygous fragile X female

KW - Martin Bell syndrome

UR - http://www.scopus.com/inward/record.url?scp=0026018777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026018777&partnerID=8YFLogxK

U2 - 10.1002/ajmg.1320380272

DO - 10.1002/ajmg.1320380272

M3 - Article

C2 - 2018094

AN - SCOPUS:0026018777

VL - 38

SP - 503

EP - 504

JO - American Journal of Medical Genetics

JF - American Journal of Medical Genetics

SN - 1552-4825

IS - 2-3

ER -